Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

25.45
+0.70002.83%
Post-market: 25.450.00000.00%16:59 EDT
Volume:296.73K
Turnover:7.49M
Market Cap:699.90M
PE:-9.47
High:25.77
Open:25.17
Low:24.78
Close:24.75
Loading ...

Aligos Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
11 Mar

OnKure Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
11 Mar

Protara Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
11 Mar

Oppenheimer Adjusts Price Target on OnKure Therapeutics to $30 From $35, Keeps Outperform Rating

MT Newswires Live
·
11 Mar

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

GlobeNewswire
·
11 Mar

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

GlobeNewswire
·
11 Mar

Atossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifen

TIPRANKS
·
11 Mar

Knight Therapeutics to Acquire Paladin Pharma for C$120M

Dow Jones
·
11 Mar

Press Release: DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025

Dow Jones
·
11 Mar

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

GlobeNewswire
·
11 Mar

Ovid Therapeutics Q4 2024 GAAP EPS $(0.13) Beats $(0.16) Estimate, Sales $76K Miss $189.286K Estimate

Benzinga
·
11 Mar

Astria Therapeutics Q4 EPS $(0.44) Beats $(0.45) Estimate

Benzinga
·
11 Mar

Press Release: Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Dow Jones
·
11 Mar

Press Release: Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Dow Jones
·
11 Mar

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

GlobeNewswire
·
11 Mar

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Business Wire
·
11 Mar